Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial.

By U. Chaudhari, P. Romano, L. Mulcahy, L. Dooley, D. Baker, Alice B. Gottlieb. The Lancet, 2001

950 citations recorded by the source corpus.

Subfields: Dermatology, Immunology, Rheumatology

View Paper: https://www.semanticscholar.org/paper/78083a28aebfe1b4756ae6831ec47c46ddd7c3f2

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Dermatology

1. D. Cua

In Immunology

1. R. Kastelein
2. T. Mcclanahan
3. W. Blumenschein
4. D. Cua
5. Christopher A. Hunter
6. R. Flavell
7. C. Weaver
8. M. Karin

Citations in the corpus

• Binding and functional comparisons of two types of tumor necrosis factor antagonists. (2002, background): “In addition, infliximab and etanercept have been studied in small, placebocontrolled trials of psoriasis patients with different levels of clinical benefit (Mease et al., 2000; Chaudhari et al., 2001).”
• Etanercept as monotherapy in patients with psoriasis. (2003, neutral): “0 (Good) 0 3 (2) 18 (11) 32 (20) 11 (7) 29 (18) 55 (34)”
• IL-23 stimulates epidermal hyperplasia via TNF and IL-20R2–dependent mechanisms with implications for psoriasis pathogenesis (2006, background): “This observation is consistent with the effi cacy of anti-TNF–directed therapies in psoriasis (27, 28).”